ProUroCare Appoints Life Science Veteran as Interim Chief Operating Officer
December 13 2012 - 7:00AM
Business Wire
ProUroCare Medical Inc. (OCTQB: PUMD), developer of the
FDA-approved ProUroScan™ prostate imaging system, announced that
life sciences veteran Doris Engibous has entered into a contract to
act as its interim Chief Operating Officer. Ms. Engibous’ primary
assignment during this interim period is to direct activities
leading to a 510(k) submission for a reusable probe for the
ProUroScan system, the placements of systems at key opinion leader
sites, and the production of systems in advance of market launch.
Chairman of the Board, Dr. Michael Chambers, commented, “We are
delighted to have someone with Doris’ track record of focus on
product development and market adoption with financial and
operational experience in both emerging and established
businesses.”
ProUroCare Board member Larry Getlin added, “I have known Doris
for many years. Not only is she a fabulous addition to the
company's bench strength as we move towards commercialization, but
she has considerable experience in navigating partnership
opportunities with both corporate and institutional players.” Rick
Carlson, ProUroCare’s President and CEO, explained, “As we execute
beyond initial FDA approval, the work to prepare for
commercialization has increased dramatically. Doris can hit the
ground running and is a great fit with our team.”
Ms. Engibous commented, “I am excited about my new
responsibilities. My mission is clear. We have identified our short
term critical milestones towards commercialization and my job is to
ensure that we accomplish all tasks necessary to meet every one of
them.” Ms. Engibous is past President and CEO of Hemosphere, Inc.,
former President of Nellcor (a business of Tyco Healthcare, now
Covidien) and serves on the board of Natus Medical (NASDAQ:
BABY).
About ProUroCare Medical Inc.
ProUroCare Medical Inc. is a publicly traded company engaged in
the business of creating innovative medical imaging products. The
company’s ProUroScan system, an elasticity imaging technology used
to document abnormalities of the prostate previously detected by a
digital rectal examination, received commercial clearance from the
FDA in April 2012. Based in Minneapolis, the company’s stock trades
on the OTCQB market (www.otcmarkets.com).
This news release contains certain "forward-looking" statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements are typically preceded by words such as
"believes," "expects," "anticipates," "intends," "will," "may,"
"should," or similar expressions. These forward-looking statements
are not guarantees of ProUroCare's future performance and involve a
number of risks and uncertainties that may cause actual results to
differ materially from the results discussed in these statements.
Factors that might cause ProUroCare's results to differ materially
from those expressed or implied by such forward looking statements
include, but are not limited to, the ability of ProUroCare to find
adequate financing to complete the development of its products; the
high level of secured and unsecured debt incurred by ProUroCare;
the impact and timing of actions taken by the FDA and other
regulatory agencies with respect to ProUroCare’s products and
business; the dependence by ProUroCare on third parties for the
development and manufacture of its products; and other risks and
uncertainties detailed from time to time in ProUroCare's filings
with the Securities and Exchange Commission including its most
recently filed Form 10-K and Form 10-Q. ProUroCare undertakes no
duty to update any of these forward-looking statements.
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Nov 2024 to Dec 2024
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Dec 2023 to Dec 2024
